Applied DNA Q1 revenue down 83% to $891K; operating loss widens to $3.8M

BNB PLUS CORP.

2024-Q1 EPS reported -$0.09 revenue$891,164

Revenue $891K vs $5.3M YoY, down 83% due to COVID-19 testing decline (CUNY contract ended) and lower cotton DNA tagging revenue.
Operating loss $3.8M vs $1.2M YoY; Adjusted EBITDA negative $3.2M vs negative $1.1M.
Cash $3.4M at Dec 31 vs $7.2M at Sep 30; post-quarter closed $3.44M direct offering with warrants.
Company projects initial GMP facility capacity enabling up to $15M annual Linea IVT revenue, expected online H1 2024.
Clinical-stage mRNA customer evaluation: Linea IVT templates met/exceeded all metrics, fastest manufacturing speed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BNB PLUS CORP. reported the three-month period ended December 31, 2023 results: revenue approximately $891 thousand.

Period: the three-month period ended December 31, 2023
Revenue: approximately $891 thousand
Result: reported results

Exact text from the filing

Total revenues were approximately $891 thousand for the three-month period December 31, 2023, compared to $5.3 million for the same period in the prior fiscal year.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

BNB PLUS CORP. filing history →

Source: SEC EDGAR

accession 0001104659-24-012280

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.